IQVIA (IQV) Q3 2025 10-Q Quarterly Report
Filed: Oct 28, 2025Period ending Sep 30, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR IQVIA (IQV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
IQVIA Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $4,100M Q3 2025, up 5.2% YoY ($204M increase); Technology & Analytics +$52M, R&D +$73M, Contract Sales +$25M
- • Operating margin decreased: Segment profit $1,555M YTD, down 1.3% YoY ($21M); Technology & Analytics profit +1.6%, R&D profit -4.3%, Contract Sales profit +5.9%
Risk Factors
- • No new or changed risk factors since 2024 Form 10-K
- • Continued exposure to regulatory risks in global healthcare compliance
IQVIA Q3 2025 Quarterly FinancialsXBRL
Revenue
$4.1B
▲ +5.2% YoY▲ +2.1% QoQ
Net Income
$331M
▲ +16.1% YoY▲ +24.4% QoQ
Operating Margin
13.5%
▼ -63bp YoY▲ +89bp QoQ
Net Margin
8.1%
▲ +76bp YoY▲ +145bp QoQ
ROE
5.4%
Total Assets
$28.7B
EPS (Diluted)
$1.92
▲ +23.9% YoY▲ +24.7% QoQ
Operating Cash Flow
$908M
▲ +25.9% YoY▲ +105.0% QoQ
Source: XBRL data from IQVIA Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other IQVIA Quarterly Reports
Get deeper insights on IQVIA
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.